Fagron NV/€FAGR

05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX

About Fagron NV

Fagron NV is a pharmaceutical company specializing in pharmaceutical compounding, providing personalized medical solutions to hospitals, pharmacies, clinics, and patients across more than 30 countries. The company operates through three segments: Essentials, offering pharmaceutical raw materials and equipment; Brands, developing innovative compounding concepts and formulations; and Compounding Services, delivering ready-to-use medications from its sterile and non-sterile facilities. Founded in 1990 in Rotterdam, the Netherlands, Fagron has expanded its operations globally, with its registered office in Nazareth, Belgium, and operational headquarters in Rotterdam. The company's strategic focus on innovation and quality has enabled it to establish a significant presence in the pharmaceutical compounding market.

Ticker

€FAGR
Sector

Primary listing

BSE

Employees

3,989

Fagron NV Metrics

BasicAdvanced
€1.5B
17.76
€1.17
0.24
€0.25
1.18%

Bulls say / Bears say

Fagron reported record first-quarter revenue of €238.7 million, up 14.1% as reported and 12.6% organic growth at CER, reflecting strong performance across all regions and segments. (Reuters)
At Capital Markets Day, Fagron unveiled mid-term targets, including organic revenue CAGR in the high single-digit to low double-digit range and a REBITDA margin near 21% by 2027, reinforcing its long-term growth strategy. (Reuters)
The FDA has recognized Fagron’s corrective actions at its Wichita facility, confirming that recent improvements effectively address prior inspection concerns, underscoring strengthened quality controls. (Reuters)
Revenue growth slowed to 6.4% in Q3 2025, down from double-digit rates earlier in the year, signaling possible difficulties in keeping up momentum. (Reuters)
An FDA Warning Letter issued in December 2024 documented several significant CGMP violations at Fagron's Wichita sterile facility, putting the company at risk for regulatory penalties and reputational harm. (FDA)
Fagron’s debt-to-equity ratio is around 69%, which may restrict financial flexibility and limit opportunities for future investments. (Simply Wall St)
Data summarised monthly by Lightyear AI. Last updated on 9 Oct 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.

Buy €FAGR

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs
Buy Fagron NV stock | €FAGR Share Price | Lightyear